Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma
Context: Osteosarcoma is the most common primary solid malignancy of the bone, mainly affecting pediatric patients. The main clinical issues are chemoresistance and metastatic spread, leading to a survival rate stagnating around 60% for four decades. Purpose: Here, we investigated the effect of simv...
Guardado en:
Autores principales: | Adèle Mangelinck, Nadia Habel, Audrey Mohr, Nathalie Gaspar, Bojana Stefanovska, Olivia Fromigué |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a4b48723a9fb48919cb3617c384370ae |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
por: Adèle Mangelinck, et al.
Publicado: (2019) -
Mvda is required for zebrafish early development
por: Wong,Wenghong, et al.
Publicado: (2021) -
Statins and risk of breast cancer recurrence
por: Sakellakis M, et al.
Publicado: (2016) -
The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis
por: Andries Heida, et al.
Publicado: (2021) -
New Approach For Simvastatin As An Antibacterial: Synergistic Effect With Bio-Synthesized Silver Nanoparticles Against Multidrug-Resistant Bacteria
por: Figueiredo EP, et al.
Publicado: (2019)